AML

This study tests a new automated method to select specific stem cells (CD34+) for transplant in people with blood cancers like leukemia or lymphoma. The goal is to lower the risk of graft-versus-host disease, a serious complication where donor cells attack the patient's body. Abo…

This early-phase study tests whether specially engineered donor immune cells (TSC-100 or TSC-101) can safely prevent blood cancers like AML, MDS, or ALL from coming back after a stem cell transplant. About 75 adults will receive either standard transplant care or these enhanced c…

This study tests whether a cord blood transplant can help children and young adults (up to age 21) with life-threatening blood cancers or genetic blood disorders who do not have a matched family donor. The main goal is to see how many patients survive one year after the transplan…

This early-phase trial tests a new drug called revumenib added to standard chemotherapy and a targeted therapy (midostaurin) for people with a specific genetic type of acute myeloid leukemia (AML). The goal is to find a safe dose and see how well it works to put the cancer into r…

This early-phase study tests a new drug called CG009301 in adults with blood cancers (like leukemia or MDS) that returned or didn't respond to standard treatments. The main goals are to find a safe dose and see if the drug can help control the disease. About 45 participants will …

This study tests whether giving two drugs (decitabine and filgrastim) after a stem cell transplant can safely prevent cancer from coming back in children and young adults with acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), or related blood cancers. About 37 partic…

This study is for people newly diagnosed with a type of acute myeloid leukemia (AML) that has a specific genetic change called FLT3 mutation, which makes the disease harder to treat. The trial will test a combination of three drugs—gilteritinib, venetoclax, and azacitidine—to see…

This early-stage study tests a new drug called ziftomenib combined with standard treatments for people with a type of acute myeloid leukemia (AML) that has come back or not responded to therapy. The main goal is to check safety and find the best dose. About 171 adults with specif…

This study is for people aged 14 to 60 with a specific genetic type of acute myeloid leukemia (AML) called RUNX1-RUNX1T1. It compares two different doses of a chemotherapy drug (cytarabine) given with another drug (anthracycline) to see which works better at improving survival. T…

This early-stage study tests a new treatment called CER-1236 for people with certain blood cancers (acute myeloid leukemia, myelodysplastic syndrome, or myelofibrosis) that have not responded to standard therapy. CER-1236 is made from a patient's own immune cells, which are modif…

This study tests a new way to prepare donor stem cells for transplant in people with blood cancers like leukemia. By removing certain immune cells from the donated cells, researchers hope to lower the risk of graft-versus-host disease, a serious side effect. The study involves 70…

This study is testing a three-drug combination (venetoclax, ivosidenib, and azacitidine) in adults with a specific genetic form of acute myeloid leukemia (AML) called IDH1-mutated. The goal is to see if this combination can improve remission rates and survival. About 23 participa…

This study compares two drug combinations to prevent graft-versus-host disease (GVHD) in people aged 65 and older with blood cancers like AML who receive a stem cell transplant. Participants will get either cyclophosphamide, sirolimus, and MMF or cyclophosphamide, sirolimus, and …

This study tests whether giving two common heart medications (a beta blocker and an ACE inhibitor) during intensive chemotherapy can prevent heart damage in people newly diagnosed with acute myeloid leukemia (AML). About 70 adults will be randomly assigned to receive the heart dr…

This study tests a new drug called JAB-8263 in adults with advanced solid tumors or blood cancers that have stopped responding to standard treatments. The goal is to find the safest dose and see if the drug can shrink tumors. About 152 people will take part in this early-phase tr…

This study tests whether giving special immune cells (memory-like NK cells) after a stem cell transplant can help control high-risk acute myeloid leukemia (AML) in children and adults. About 68 participants will receive donor stem cells followed by these NK cells. The goal is to …

This study tests a stem cell transplant using a milder chemotherapy combination (treosulfan and fludarabine) followed by donor stem cells and drugs to prevent graft-versus-host disease. It includes 132 people aged 2-75 with blood cancers like AML or MDS. The goal is to see if thi…

This early-stage trial tests a combination of two drugs, CC-486 and venetoclax, in people with acute myeloid leukemia (AML) whose cancer has returned or not responded to treatment, as well as some newly diagnosed patients. The main goal is to find the safest dose of CC-486 when g…

This study looks at whether levels of a protein called leptin in bone marrow fluid can help predict how well chemotherapy works in adults with acute myeloid leukemia (AML). Researchers will measure leptin before treatment and compare it to response rates. The goal is to find a wa…

This study looks at how the body processes venetoclax when the tablets are crushed and mixed into a liquid for children and young adults with blood cancers like leukemia or lymphoma. About 30 participants who already take venetoclax this way will have their blood levels measured.…

This study aims to find out if certain substances in the bone marrow can predict how well adults with acute myeloid leukemia (AML) will respond to chemotherapy. Researchers will measure levels of IL-6, leptin, and fumarate in bone marrow samples from 405 newly diagnosed AML patie…

This study follows about 1,000 people who previously received an experimental T-cell therapy (TSC-100 or TSC-101) for blood cancers like AML, ALL, or MDS. Researchers will monitor participants for up to 15 years to track any side effects and see how well the therapy works over ti…

This research study aims to discover new genes that may increase the risk of childhood cancer. Researchers will collect blood samples and health information from 1,500 people in families where cancer clusters. The goal is to build a registry and sample bank to help future diagnos…